Suzuken Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022
November 12, 2021 at 01:00 am EST
Share
Suzuken revised earnings guidance for the fiscal year ending March 31, 2022. Based on the financial results of second quarter announced yesterday, the company has revised the company's earnings forecast by incorporating the results of the voluntary retirement program and impact of the sale of investment securities. The company will continue by explaining the full-year financial forecast for the fiscal year ending March 2022. Witness, sales increased. Operating income and ordinary income declined; however, an increase in final profits is expected.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
SUZUKEN CO., LTD. 
